

Bioactive Lipids: Biochemistry and Diseases

Sponsored by Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited.

Also supported by the Japan Society for the Promotion of Science in cooperation with Kyoto University.

June 6–11, 2010 • Westin Miyako Kyoto • Kyoto • Japan

Scientific Organizers: Shuh Narumiya, Takao Shimizu and Garret A. FitzGerald

PROGRAM FACULTY & TALKS

Junkin Aoki, Tohoku University, Japan

Talk Title to be Determined

K. Frank Austen, Harvard Medical School, USA

Integrated Biology of cysLTs and their Multiple Receptors

Alan R. Brash, Vanderbilt University Medical Center, USA

Enzymology and Biology of Epithelial Lipooxygenases

Kenji Chiba, Mitsubishi Tanabe Pharma Corporation, Japan

Immunoregulation by the Sphingosine 1-Phosphate Receptor Modulator, FTY720

Jerold J. Chun, The Scripps Research Institute, USA

Talk Title to be Determined

Shaun R. Coughlin, University of California, San Francisco, USA

S1P Signaling and the Cardiovascular System

Jilly F. Evans, Amira Pharmaceuticals, USA

FLAP Inhibitors

Garret A. FitzGerald, University of Pennsylvania, USA

Cardiovascular Biology of the Prostanoids

Colin D. Funk, Queen's University, Canada

Eicosanoids in Cardiovascular Disease

Jesper Z. Haeggstrom, Karolinska Institute, Sweden

Structure and Function of LTA4 Hydrolase, LTC4 Synthase and Related Enzymes

Osamu Hayaishi*, Osaka Bioscience Institute, Japan

Prostaglandins and Sleep

B. Therese Kinsella, University College Dublin, Ireland

Biochemistry of IP

Andrew D. Luster, Massachusetts General Hospital, USA

Lipid Mediators, Chemokines and T Cells

Takayuki Maruyama, Minase Research Institute, Ono Pharmaceutical Co. Ltd., Japan

EP Agonists and Antagonists

Makoto Murakami, Tokyo Metropolitan Institute of Medical Science, Japan

Biological Functions of sPLA2s

Robert C. Murphy, University of Colorado Denver, USA

Transcellular Biosynthesis of Leukotrienes in vivo

Shuh Narumiya, Kyoto University, Japan

Prostanoids and T Cells

Gary Paul O'Neill, Merck Frosst Center for Therapeutic Research, Canada

DP1 Antagonists and Niacin

Suzanne Ostrand-Rosenberg, University of Maryland, USA

PGE2/Myeloid-Derived Suppressor Cells

Paola Patrignani, G. D'Annunzio University, Italy

Role of Prostanoids in Endothelial Biology

Daniele Piomelli, University of California, Irvine, USA

Endocannabinoids and the Brain

Michal L. Schwartzman, New York Medical College, USA

Cytochrome P450-Derived EETs and HETEs in Vascular Biology

Takao Shimizu, University of Tokyo, Japan

Membrane Lipid Metabolism and Lipid Mediators

William L. Smith, University of Michigan, USA

COX Isoforms

Sarah Spiegel, Virginia Commonwealth University School of Medicine, USA

Sphingosine-1-Phosphate in Allergy and Inflammation

John Turk, Washington University School of Medicine, USA

Physiological Role of iPLA2

Yoshihiro Urade, Osaka Bioscience Institute, Japan

Talk Title to be Determined

Kikuko Watanabe, University of East Asia, Japan

A Novel Type of PGF Synthase belonging to the Thioredoxin-like Superfamily

Andreas Zimmer, University of Bonn, Germany

Endocannabinoids and Immunoregulation

*Keynote speaker. Program subject to change. Current as of January 5, 2010.



The world of lipid mediators is expanding. New and unexpected biological functions, biosynthetic pathways and receptors are being revealed for lipids as appreciation of their complex interactions with protein and DNA grows. New actions are still being added to classic mediators such as prostaglandins and leukotrienes. Lipid mediators are now recognized to influence a broad swathe of biology from inflammation to allergy, immunity, cardiovascular diseases, cancer and behavior. Advances in lipidomics enable us to monitor dynamics of a variety of lipid mediators simultaneously. In this symposium we invite distinguished scientists to share their progress in this expanding field and to present a comprehensive view on what lipid mediators do in our body. We also invite scientists interested in the translation of such basic science from model systems to an understanding of the role of lipids in human physiology, disease and drug action. Expansion of our understanding of the role of lipid mediators affords the opportunity for novel therapeutic opportunities, examples of which will be discussed in the symposium.

PROGRAM PLENARY SESSIONS:

- Biochemistry of Lipid Metabolism I, II and III
- Immunoregulation
- Allergy and Inflammation
- Nervous System
- Cardiovascular Diseases I and II
- Immunomodulation by Lipid Mediators and Related Drugs

DEADLINES:

Abstract & Scholarship: February 23, 2010

Late-Breaking Abstract: March 9, 2010

Early Registration: April 6, 2010

www.keystonesymposia.org/10D2

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

PO Box 1630 • Silverthorne, CO 80498 • USA
www.keystonesymposia.org • 1-800-253-0685 • 1-970-262-1230